Protalix BioTherapeutics, Inc. (PLX) Net Income by Year
Protalix BioTherapeutics, Inc. reported a net loss of $6.6M in fiscal year 2025. This represents a decrease of 325.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $18.9M in net income. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Protalix BioTherapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
PLX Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $18.9M | -$6.6M-325.2% | $2.9M-64.7% | $8.3M+155.7% | -$14.9M+45.9% | -$27.6M-322.8% | -$6.5M+64.3% | -$18.3M+30.9% | -$26.5M+68.3% | -$83.4M-184.1% | -$29.4M-150.6% | $58.0M+293.8% | -$29.9M-7.7% | -$27.8M-139.2% | -$11.6M+68.2% | -$36.5M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
PLX Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Protalix BioTherapeutics, Inc. financials
Frequently Asked Questions
What was Protalix BioTherapeutics, Inc.'s net income in fiscal year 2025?
Protalix BioTherapeutics, Inc. reported a net loss of $6.6M in fiscal year 2025.
How fast is Protalix BioTherapeutics, Inc.'s net income growing?
Protalix BioTherapeutics, Inc. (PLX) net income fell by 325.2% year over year, from $2.9M to -$6.6M in fiscal year 2025.
What is Protalix BioTherapeutics, Inc.'s net income over the last twelve months?
Protalix BioTherapeutics, Inc. (PLX) reported $18.9M in net income over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Protalix BioTherapeutics, Inc.'s net income changed over the years?
Across the 15 fiscal years this page covers, Protalix BioTherapeutics, Inc. (PLX) net income went from -$36.5M in fiscal year 2011 to -$6.6M in fiscal year 2025.
What was Protalix BioTherapeutics, Inc.'s net income in the most recent quarter?
Protalix BioTherapeutics, Inc. (PLX) reported $3.8M in net income in Q2 2026. This represents an increase of 2203.0% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Protalix BioTherapeutics, Inc. (PLX) reported on that line in every period on record.